Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development - A Workshop

Committee

Carlos Blanco

Co-Chair

Carlos Blanco, M.D., Ph.D; is the Director of the Division of Epidemiology, Services, and Prevention Research at the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH). Blanco is a national known expert in the epidemiology and treatment of addictive disorders with and without comorbid disorders. His accomplishments include, among others, a detailed examination of the course and stages of substance use disorders, the development of methods to quantify the generalizability of clinical trials, the development and testing of interventions that combine motivational interviewing with cognitive-behavioral therapy to improve retention and outcome in individuals with addictive disorders, and the creation of a virtual map of psychiatric disorders, based on empirical data, to guide research into the causes of mental disorders. Prior to joining NIDA, Blanco was Professor of Psychiatry at Columbia University Medical Center and a Research Psychiatrist at the New York State Psychiatric Institute. He is a graduate of Universidad Autónoma de Madrid (Spain) and completed his psychiatry residency at Columbia University, where he also completed a research fellowship. Blanco has authored over 200 peer-reviewed publications.

Craig B. Surman

Co-Chair

Craig B.H. Surman, M.D.; is Director of the Clinical and Research Program in Adult ADHD and Staff Neuropsychiatrist at Massachusetts General Hospital (MGH). Surman investigates and educates disorders of self-regulation as an Associate Professor of Psychiatry at Harvard Medical School. He is co-chair of the Children and Adults with ADHD (CHADD) Professional Advisory Board, and a former Board member for the American Professional Society of ADHD and Related Disorders (APSARD), where he serves on the Board nominating committee. With international experts, he created “ADHD in Adults: A Practical Guide to Evaluation and Management.” An advocate for evidence-informed care, he co-authored “FAST MINDS: How To Thrive If You Have ADHD (or think you might).” Contributing to over 50 investigations, he has illuminated the connection between Adult ADHD and comorbidities, and clarified the promise of novel behavioral, pharmacologic, and nutraceutical interventions for ADHD. Surman recently piloted application of remote digital measurement in ADHD treatment monitoring and in a clinical trial. He is currently serving as a monitor for ADHD symptom ratings in an ongoing clinical trial at MGH Brigham that is contracted through Neurocentria. He has previously consulted for Kaya, Neurocentria, and other companies and conducted clinical trials at MGH that have been supported by Abbot, Cephalon, Hilda and Preston Davis Foundation, Eli Lilly, Magceutics/Neurocentria, Jazz/Axsome, Johnson & Johnson/McNeil, Lundbeck, Merck, Nordic Naturals, Shire, and Takeda. To understand factors contributing to national ADHD treatment trends, he is currently collaborating with the Centers for Disease Control. He is a graduate of Oberlin College, University of Massachusetts Medical School, and completed residency and fellowship training at Harvard Medical School.

Amy F. Arnsten

Member

Amy F.T. Arnsten, Ph.D; is the Albert E. Kent Professor of Neuroscience at the Yale University School of Medicine. She is an international expert on the molecular regulation of the primate prefrontal cortex, the brain region most often afflicted in ADHD, and has developed a nonstimulant treatment for ADHD, guanfacine (Intuniv), that was FDA-approved for this indication in 2009. This is one of the few examples where knowledge arising from basic science has successfully translated to a treatment for human cognitive disorders. Guanfacine is also being used off-label to treat other prefrontal cortical disorders, including cognitive deficits from long-COVID. Arnsten is a member of the National Academy of Medicine and the recipient of the Goldman-Rakic Prize for Outstanding Research in Cognitive Neuroscience. She received her B.A. in Neuroscience from Brown University in 1976, creating the Neuroscience major, and her Ph.D. in Neuroscience from University of California, San Diego in 1982.

Andrea M. Chronis-Tuscano

Member

Andrea M. Chronis-Tuscano, Ph.D; is a Professor of Psychology at the University of Maryland (UMD), College Park, and the Director of the UMD Students Understanding College Choices Encouraging and Executing Decisions for Success (SUCCEEDS) College Attention-Deficit/Hyperactivity Disorder (ADHD) Clinic. Chronis-Tuscano's research focuses broadly on understanding early predictors of developmental outcomes for children with ADHD (including depression and alcohol/substance use) and developing novel treatments which target these early risk and protective factors. Much of this research has addressed issues related to maternal parenting and psychopathology (namely, maternal depression and ADHD). Most recently, she has utilized hybrid effectiveness-implementation designs to develop treatments that can be implemented in community settings such as pediatrics and schools. Chronis-Tuscano is also the President-Elect of the Society for Clinical Child and Adolescent Psychology (APA Division 53); Past-President of the International Society for Research in Child and Adolescent Psychopathology; past Associate Editor of the Journal of Consulting & Clinical Psychology; Fellow of the Association for Psychological Science; Fellow of the Association for Behavioral & Cognitive Therapies (ABCT); former Associate Editor of the Journal of Clinical Child & Adolescent Psychology; and former standing member of the National Institute of Mental Health (NIMH) Mental Health Services Research (SERV) review committee. She is the recipient of multiple National Institute of Health (NIH) grants and has served on several NIH review committees relevant to developmental psychopathology and interventions.

Taleed El-Sabawi

Member

Taleed El-Sabawi, J.D., Ph.D.; is an interdisciplinary scholar, with a J.D. and a Ph.D. in Public Health, Health Services Management and Policy with a doctoral cognate in Political Science. Her area of expertise is in addiction and mental health policy, politics, and law, specifically contemporary issues at the intersection of addiction, race, and policing. El-Sabawi is a person with lived experience with ADD, adult diagnosis of ADD, and has been personally affected by the stimulant shortage. In addition to her scholarship, El-Sabawi has played an active role in advising federal, state, and local governments, including the Office of National Drug Control Policy, U.S. Department of Justice, Jails Division, and N.C.'s Attorney General's Office. She has drafted a model law for the creation of non-police behavioral health crisis response teams, which is being circulated by organizers in New Orleans (LA), Nashville (TN), Columbus (OH), Chicago (IL), Boston (MA), and Durham (NC). El-Sabawi is on the advisory circle of the North Carolina Urban Survivors Union, a chapter of the Urban Survivors Union, on the Board of Directors for Next Distro and frequently works alongside persons who use drugs advocating for policy reform.

Tamara Rosier Emigh

Member

Tamara Rosier, Ph.D.; is founder of the Attention-Deficit/Hyperactivity Disorder (ADHD) Center of West Michigan, where she and her staff of coaches and therapists, work with individuals with ADHD (and their families) to learn strategies and develop new skills to live effectively with ADHD. Rosier's experiences as a college administrator, a professor, and a high school teacher afforded her valuable insight into ADHD and how it affects one's life. She is also the president of the ADHD Coaches Organization and co-chair of the International Conference on ADHD. She has published numerous articles about living with ADHD and frequently speaks at conferences. Her book, Your Brain's Not Broken, provides strategies for managing the emotional aspects of ADHD.

Evelyn Joella Polk Green

Member

Evelyn Green, M.S.Ed.; is a past national president of both the Attention Deficit Disorder Association (ADDA) and Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD). She is an adult with attention-deficit/hyperactivity disorder (ADHD), and the mother of two adult sons both of whom also have ADHD. Active in ADHD and mental health advocacy for close to 30 years, she has served as a leader representing the family voice in the ADHD and mental health communities in many capacities, including as a member of the Network on Children’s Mental Health Services funded by the MacArthur Foundation. She frequently represents the family/consumer perspective on mental health issues and often speaks to audiences and the media on a variety of topics. She has been focused on the challenges of ADHD in minority, poor, and other underserved populations throughout her advocacy career. She is the recipient of several honors for her volunteer work in mental health and education, including the Beacon College Achieving Lifetime Vision and Excellence (ALiVE) Award for her advocacy work on behalf of children and adults with learning differences and ADHD. Green works as an administrator with the Chicago Public Schools, planning professional development programs for early childhood special education professionals and families. She holds bachelor and master’s degrees from National Louis University and a master’s degree from Northern Illinois University.

Steve S. Lee

Member

Steve S. Lee, Ph.D; is a Professor of Psychology and the Director of Clinical Psychology Training in the Department of Psychology at the University of California, Los Angeles (UCLA). He completed his undergraduate degree in psychology at the University of Chicago, his doctoral training in clinical psychology at UC Berkeley, and then post-doctoral training in psychiatric genetics at the University of Chicago. He is an expert in the origins, development, and outcomes of youth with ADHD and related disruptive behavior and emotional problems. His program of research leverages diverse methods spanning microanalytic coding of behavior and longitudinal designs to meta-analytic reviews. Lee was past Secretary/Treasurer of the International Society for Research in Child and Adolescent Psychopathology and Past-President of the Society for Clinical Child and Adolescent Psychology. He was the recipient of the 2021 Mavis Hetherington Award for Excellence in Applied Developmental Science from the American Psychological Association.

James Leonard

Member

James (Jimmy) Leonard, Pharm.D., DABAT; is the Director of Clinical Services for the Maryland Poison Center and an Associate Professor at the University of Maryland School of Pharmacy. His practice and research focus on management and prevention of poisoning including exploratory ingestions in children, medication errors in all populations, and self-harm attempts in adolescents and adults. He is a member of the American Association of Clinical Toxicology and America’s Poison Centers (formerly American Association of Poison Control Centers). He is the chair of the data access committee for America’s Poison Centers. He attended Washington State University for undergraduate and pharmacy school, followed by a one-year hospital residency in Olympia, Washington. After completion of residency, he did a two-year fellowship in Clinical Toxicology from 2017-2019 before joining the staff at the Maryland Poison Center and subsequently the faculty at the University of Maryland School of Pharmacy.

Matthew Rudorfer

Member

Matthew Rudorfer, M.D.; a longtime Medical Officer at the National Institute of Mental Health (NIMH), is Chief of the Psychopharmacology, Somatic, and Integrated Treatment Research Program, Treatment and Preventive Interventions Research Branch, in the NIMH Division of Services and Intervention Research. In this capacity he oversees grants and contracts supporting clinical trials, including pharmacotherapy studies, primarily in adults suffering from a range of mental disorders. In the past he served for a dozen years as Program Chair or Co-Chair of the annual New Clinical Drug Evaluation Unit (NCDEU) national treatment research meeting, which brought together clinical investigators from Government, academia, and industry. Following a term as Member and Chair of the FDA Psychiatric Drugs Advisory Committee, he remains an ad hoc voting member, providing uncompensated service to multiple advisory committees over the years. He is also past Editor-in-Chief of the peer-reviewed Psychopharmacology Bulletin. At present, he serves on the editorial boards of CNS Drugs and the Journal of ECT. In addition to his work at NIMH, Dr. Rudorfer maintains a small private practice in psychiatry and psychopharmacology. He is Board-Certified in Psychiatry and Clinical Pharmacology, and is a member of the American Society of Clinical Pharmacology and Therapeutics (ASCPT), the American Society of Clinical Psychopharmacology (ASCP), the Society of Biological Psychiatry, and the American Psychiatric Association. At present, he is Chair of the Continuing Medical Education (CME) Committee of the Washington Psychiatric Society. After receiving his medical degree from the State University of New York, Downstate College of Medicine, Rudorfer undertook his residency in Psychiatry at Washington University in St. Louis, followed by a National Institute of General Medical Science (NIGMS) Fellowship in Clinical Pharmacology, prior to launching his research career, studying novel medications for the treatment of mood disorders, in the NIMH intramural program.

Almut G. Winterstein

Member

Almut G. Winterstein, Ph.D.; is Distinguished Professor in Pharmaceutical Outcomes and Policy, Affiliate Professor in Epidemiology, and the founding Director of the Center for Drug Evaluation and Safety at the University of Florida. In 2017, she was named the Dr. Robert and Barbara Crisafi Chair for Medication Safety in recognition of her research on drug safety and on devising ways to improve medication use. Winterstein’s research interests center on the post-marketing evaluation of drugs in pediatrics and pregnancy, infectious disease and psychiatry and the evaluation of policy surrounding medication use using real-world data. As expert in drug safety, she has chaired the Food and Drug Administration’s Drug Safety and Risk Management Advisory Committee from 2012-2018. Winterstein was inducted as a fellow of the International Society of Pharmacoepidemiology in 2013 and served as president of the society from 2019-2020. Since 2019 she serves as director of the Consortium for Medical Marijuana Clinical Outcomes Research, a state-funded consortium of 9 universities in Florida. In 2022 she was inducted in the Academy of Science, Engineering and Medicine in Florida. Dr. Winterstein is currently consulting with Merck, Sharp, and Dohme is in regards to one of their vaccines (unrelated to stimulants). She received her pharmacy degree from Friedrich Wilhelm University in Bonn, Germany, and her Ph.D. in Pharmacoepidemiology from Humboldt University in Berlin.

Stevin H. Zorn

Member

Stevin H. Zorn, Ph.D.; is currently President, and CEO of MindImmune Therapeutics Inc., a company targeting the immune system to treat diseases of the CNS; Ryan Research Professor of Neuroscience, at the George and Anne Ryan Institute for Neuroscience, and adjunct Full Professor of Biomedical and Pharmaceutical Sciences at the College of Pharmacy both at the University of RI; and President of SH Zorn Consulting LLC, a company specializing in Neuroscience pharmaceutical industry consulting. Previously, he was Executive Vice president and Site Head for Lundbeck Research USA, and Vice president and Global Therapeutic Area Head for Central Nervous System Disorders Research Pfizer Global Research and Development. His research focus is on discovering meaningful treatments to relieve suffering from both Psychiatric and Neurological diseases with underpinnings from neuro-immune mechanisms. Dr. Zorn received a BS degree in Chemistry from Lafayette College, Easton, PA, and MS and Ph.D. degrees in Biomedical Sciences with emphasis in Neurotoxicology and Neuropharmacology, respectively, from the University of Texas Graduate School Of Biomedical Sciences, Houston, TX. Subsequent postdoctoral research studies centered on basic research of brain and intracellular neuronal signaling mechanisms at the Rockefeller University, New York, NY, in Paul Greengard’s, (Nobel Laureate) laboratory of Molecular and Cellular Neuroscience.